Sign in
4

Changes in Ownership

Axsome Therapeutics, Inc. Filed Acc 0001193125-25-234881

Chief Executive Officer sold 45,384 shares at an average $119.38 ($5,418,060)

  • Chief Executive Officer acquired 45,384 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
TABUTEAU HERRIOT Chief Executive Officer 2025-10-06 Option exercise 10b5-1 +19,220 $8.02 $154,144 26,449 D: show line 1 in the form
TABUTEAU HERRIOT Chief Executive Officer 2025-10-06 Sale 10b5-1 −19,220 $120.17 $2,309,667 7,229 D: show line 2 in the form
TABUTEAU HERRIOT Chief Executive Officer 2025-10-07 Option exercise 10b5-1 +13,390 $8.02 $107,388 20,619 D: show line 3 in the form
TABUTEAU HERRIOT Chief Executive Officer 2025-10-07 Sale 10b5-1 −13,390 $118.77 $1,590,330 7,229 D: show line 4 in the form
TABUTEAU HERRIOT Chief Executive Officer 2025-10-08 Option exercise 10b5-1 +12,774 $8.02 $102,447 20,003 D: show line 5 in the form
TABUTEAU HERRIOT Chief Executive Officer 2025-10-08 Sale 10b5-1 −12,774 $118.84 $1,518,062 7,229 D: show line 6 in the form
Open-market sales · 45,384 sh · avg $119.38 · $5,418,060

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
TABUTEAU HERRIOT Chief Executive Officer 2025-10-06 Option exercise · Stock Option (Right to Buy) 10b5-1 −19,220 441,900 D: show line 7 in the form
TABUTEAU HERRIOT Chief Executive Officer 2025-10-07 Option exercise · Stock Option (Right to Buy) 10b5-1 −13,390 428,510 D: show line 8 in the form
TABUTEAU HERRIOT Chief Executive Officer 2025-10-08 Option exercise · Stock Option (Right to Buy) 10b5-1 −12,774 415,736 D: show line 9 in the form
Loading xslF345X05/ownership.xml…